Glycogen Storage Disease Due to Muscle Beta-Enolase Deficiency

1. Disease Information

1.1 Definition, Nosology, and Disease Concept

Glycogen storage disease type XIII is defined as a rare glycolysis disorder due to severe deficiency of β‑enolase in skeletal muscle, resulting in exercise intolerance and myalgia, with or without rhabdomyolysis.[2][3][4][5][10][11] Orphanet describes the condition as “a rare glycolysis disorder characterized clinically by exercise intolerance and myalgia due to severe enolase deficiency in muscle,” emphasizing its classification among inherited metabolic myopathies rather than primary neuromuscular transmission disorders.[5] The Genetic and Rare Diseases Information Center (GARD) similarly notes that GSD XIII is an inherited disease of the muscles in which affected muscle fibers cannot produce sufficient energy to function properly, causing muscle weakness and pain.[1] The disease is grouped among glycogen metabolism disorders affecting skeletal muscle, although most of these involve enzymes in glycogenolysis or glycolysis and only a minority involve glycogen synthesis; GSD XIII occupies a specific niche as a distal glycolytic defect.[2]

From a mechanistic standpoint, GSD XIII can be conceptualized as an inborn error of energy metabolism in which the final steps of glycolysis are impaired in skeletal muscle, leading to an inability to increase ATP production via anaerobic glycolysis during high‑intensity exercise and thereby causing functional motor deficit and poor exercise tolerance.[2][3][5][11] Tarnopolsky’s comprehensive review of myopathies related to glycogen metabolism disorders lists GSD XIII as a disorder of β‑enolase (EC 4.2.1.11) due to ENO3 mutations, with autosomal recessive inheritance and main clinical features of exercise intolerance and rhabdomyolysis.[2] The disease is thus best situated within the broader nosologic category of inborn errors of metabolism, specifically glycolysis disorders and glycogen storage diseases affecting skeletal muscle, and within the clinical category of metabolic myopathies presenting with exertional symptoms.

In the context of disease ontologies, muscle β‑enolase deficiency corresponds to MONDO:0013046, and is cross‑referenced to multiple rare disease databases including Orphanet (ORPHA:99849), OMIM (612932), MedGen (C2752027), and GARD (2125).[5][6][10][12][16] It is classified under ICD‑10 code E74.0 (disorders of carbohydrate metabolism) and ICD‑11 code 5C51.3 (glycogen storage disease due to muscle β‑enolase deficiency).[5][10] These categorizations reflect both its biochemical nature as a carbohydrate metabolism disorder and its clinical expression as a muscle disease with neurological overlap.

From a conceptual standpoint, the disease exemplifies how a single enzyme defect in a ubiquitous pathway such as glycolysis can produce highly tissue‑specific clinical manifestations due to isoenzyme specialization and differential expression, in this case targeting skeletal muscle where β‑enolase is the predominant isoform.[2][3][14] The combination of extreme rarity, tissue specificity, and relatively mild chronic phenotype (with potentially severe acute episodes) has limited epidemiologic characterization but provides a clear mechanistic framework for understanding its clinical presentation, diagnosis, and management.

1.2 Identifiers, Synonyms, and Terminology

GSD XIII has multiple synonyms and alternative names across databases and publications, reflecting its biochemical, genetic, and clinical facets.[4][5][10][11][12][16] Orphanet lists the following synonyms: “GSD due to muscle beta‑enolase deficiency,” “GSDXIII,” “glycogenosis due to muscle beta‑enolase deficiency,” “glycogenosis type 13,” “muscle enolase deficiency,” and “muscular enolase deficiency,” all referring to the same disorder.[5] OMIM and Malacards use the term “Glycogen Storage Disease Type XIII,” often abbreviated as GSD13 or GSD XIII, and link it to ENOLASE 3 deficiency and ENO3‑beta deficiency.[4][10][12][16] The MONDO ontology term MONDO:0013046 is labeled “muscle beta‑enolase deficiency,” and the GARD terminology likewise refers to “glycogen storage disease due to muscle beta‑enolase deficiency.”[1][6][16]

Key identifiers across major resources include OMIM:612932 for the ENO3‑related muscle glycogen storage disease, Orphanet:99849, MedGen:C2752027, UMLS:C5566614, MONDO:0013046, and GARD:2125.[1][5][6][10][12][16] ICD‑10 and ICD‑11 codes (E74.0 and 5C51.3, respectively) support clinical coding and epidemiologic tracking.[5][10] At the gene level, ENO3 is catalogued under NCBI Gene ID 2027, HGNC symbol ENO3, and is also known as “muscle specific enolase,” “muscle enriched enolase,” “skeletal muscle enolase,” and “GSD13” in some annotations.[14][15]

It is important to distinguish muscle β‑enolase deficiency (ENO3‑related GSD XIII) from other enolase deficiencies affecting different tissues and isoforms, such as enolase‑1 (ENO1) deficiency causing red blood cell abnormalities and hemolytic anemia, which is transmitted in an autosomal dominant pattern and involves a distinct gene on chromosome 1.[10] Malacards notes that enolase deficiency can manifest in red blood cells with a spherocytic phenotype and hemolytic anemia, but this is attributable to ENO1 rather than ENO3 and represents a separate clinical entity.[10] Careful use of terminology and identifiers is therefore crucial to avoid conflating these conditions in clinical and research contexts.

1.3 Data Sources and Nature of Evidence

Given its extreme rarity, current knowledge about GSD XIII is derived primarily from individual case reports, small clinical series, biochemical and genetic characterization studies, and expert reviews, rather than population‑based registries or large cohorts.[2][3][4][5][8][10][11][17] The index case was published by Comi et al. in 2001, describing a 47‑year‑old man with exercise intolerance and myalgias who was found to have severe muscle enolase deficiency (approximately 5% residual activity) and compound heterozygous missense mutations in ENO3.[3][7][16] Subsequent early case reports from Italy and the United Kingdom expanded the clinical and biochemical spectrum and identified additional ENO3 variants.[4][8][11][17] Wigley et al. (2019) emphasized the need for biochemical confirmation of β‑enolase deficiency in the genomic era, illustrating the challenges of interpreting ENO3 variants identified by exome sequencing in ultra‑rare disorders.[8]

The comprehensive review by Tarnopolsky (2018) on myopathies related to glycogen metabolism disorders synthesizes data across multiple glycogen and glycolysis defects, including GSD XIII, and provides a comparative framework for understanding clinical features, diagnostic strategies, and therapeutic approaches.[2] Orphanet, GARD, Malacards, Metagene, MONDO, and NCBI’s Genetic Testing Registry (GTR) aggregate disease‑level information, including phenotype descriptions, identifiers, inheritance patterns, and links to genetic testing and ClinVar variant entries.[1][4][5][6][10][12][14][16] PanelApp from Genomics England includes ENO3 on its glycogen storage disease panel with “high evidence” designation, reflecting expert consensus that ENO3 mutations cause a recognized disease entity.[9]

Taken together, these resources constitute an aggregated disease‑level knowledge base grounded in human clinical data and biochemical/genetic validation but limited by the very small number of reported patients. The absence of large natural history studies or intervention trials must be explicitly acknowledged, and many aspects of epidemiology, genotype–phenotype correlation, and long‑term outcomes remain inferred or extrapolated from related metabolic myopathies rather than directly documented in GSD XIII.

2. Etiology: Causal Factors, Risk, and Protection

2.1 Genetic Causal Factors: ENO3 Variants and Autosomal Recessive Inheritance

The primary and, to date, exclusive causal factor for GSD XIII is biallelic pathogenic or likely pathogenic variants in the ENO3 gene, encoding the muscle‑predominant β‑enolase isoform of enolase.[2][3][4][5][8][10][12][14][16] ENO3 is located on chromosome 17p13.2, is a protein‑coding gene with multiple transcript variants, and is strongly expressed in skeletal muscle and heart, with biased expression in these tissues relative to others.[4][10][14][15] The β‑enolase protein functions as a homodimer (or heterodimer with other enolase isoforms in some contexts) catalyzing the reversible dehydration of 2‑phosphoglycerate to phosphoenolpyruvate, a crucial penultimate step of glycolysis.[2][3][14]

In adult human skeletal muscle, more than 90% of total enolase activity is accounted for by the β‑enolase subunit, underscoring the central role of ENO3 in muscle glycolysis.[3] Comi et al. reported that the β‑enolase protein was dramatically reduced in the muscle of their index patient, as shown by immunohistochemistry and immunoblotting, while α‑enolase was normally represented, indicating a specific deficiency of the β isoform.[3] In that patient, two heterozygous missense mutations were identified in ENO3: a c.467G>A transition causing a Gly156Asp substitution near the catalytic site, and a c.1121G>A transition causing a Gly374Glu substitution.[3][16] The mutations were inherited in trans, with the mother heterozygous for the c.467G>A variant and a sister heterozygous for c.1121G>A, consistent with autosomal recessive inheritance.[3][16] Muscle enolase activity was approximately 5% of normal, and ultrastructural analysis showed focal sarcoplasmic accumulation of glycogen β particles.[3]

ClinVar records the c.467G>A (p.Gly156Asp, also annotated as G113D in some transcripts) variant as associated with “Glycogen storage disease due to muscle beta‑enolase deficiency,” noting that advanced modeling and experimental studies have shown that this missense change affects ENO3 function and is expected to disrupt protein stability.[16] However, due to limited numbers of affected individuals and incomplete segregation data, the variant is currently classified as a Variant of Uncertain Significance (VUS) in ClinVar, illustrating the broader challenge of variant interpretation in ultra‑rare diseases.[16] The c.1121G>A (p.Gly374Glu) variant is similarly rare and has been reported in the index patient; functional characterization suggests reduced stability and enzymatic activity, but formal classification also remains constrained by limited evidence.[3][16]

Additional ENO3 variants have been reported in later cases. Wigley et al. (2019) described a patient with exercise intolerance and rhabdomyolysis carrying ENO3 variants identified by genomic sequencing; they emphasized that enzyme activity assays were necessary to confirm pathogenicity, given the lack of population‑level evidence and the presence of ENO3 missense variants in databases such as gnomAD at low frequencies.[8][16] Toscano et al. (2021) studied energy metabolism during exercise in patients with β‑enolase deficiency, implying the existence of more than one affected individual and thus additional genotypes, though detailed variant descriptions are not visible in the provided search snippet.[17] Metagene and IAMGSD summarize that approximately three cases have been reported, all with autosomal recessive mutations in ENO3.[4][11]

Collectively, these data indicate that GSD XIII is a monogenic, autosomal recessive disorder caused by germline ENO3 variants that lead to severe reduction of β‑enolase activity in skeletal muscle. The functional consequence is a loss‑of‑function phenotype characterized by decreased stability and reduced catalytic activity of mutant β‑enolase, resulting in impaired glycolytic flux during high‑demand conditions.[3][16] There is currently no evidence that somatic ENO3 mutations contribute to this disease or that copy‑number changes, chromosomal rearrangements, or epigenetic alterations play a causal role in recognized patients.[14][15][16]

2.2 Environmental and Non‑Genetic Causal Factors

There is no evidence that environmental toxins, infections, radiation, or other non‑genetic exposures directly cause GSD XIII in the absence of ENO3 mutations. The disease is consistently described as an inherited metabolic myopathy with autosomal recessive transmission, and all characterized patients have carried biallelic ENO3 variants.[3][4][5][8][10][11][12][16][17] Comparative toxicogenomics and environmental health databases have not reported associations between specific chemicals or occupational exposures and isolated muscle β‑enolase deficiency as a primary cause of disease.

However, environmental factors play an important role as triggers of symptomatic episodes and modifiers of disease expression. Strenuous or intense anaerobic exercise, particularly involving large muscle groups and conducted without adequate conditioning or hydration, is a consistent precipitant of myalgia, exercise intolerance, and rhabdomyolysis in GSD XIII.[2][3][4][5][8][11][17] IAMGSD notes that muscle pain and fatigue occur during intense activity, with normal baseline creatine kinase (CK) and rhabdomyolysis episodes linked to excessive exertion.[11] Metagene similarly lists exertion intolerance, muscle cramps, muscle weakness, and rhabdomyolysis, with onset in adulthood and skeletal muscle involvement.[4] Toscano et al.’s focus on “energy metabolism during exercise” underscores that physical activity patterns are critical determinants of symptom manifestation.[17]

Physiological stressors such as fever, systemic illness, or dehydration may further predispose individuals with GSD XIII to episodes of muscle breakdown, as is observed in other metabolic myopathies, although specific documented cases are sparse.[2] Therefore, while environmental factors are not primary etiologic causes, they are central to the clinical expression of the disease and must be considered in risk assessment and management strategies.

2.3 Risk Factors: Genetic, Environmental, and Demographic

The primary risk factor for developing GSD XIII is being homozygous or compound heterozygous for pathogenic or likely pathogenic ENO3 variants in the germline, in the setting of autosomal recessive inheritance.[3][4][5][8][12][14][16] Heterozygous carriers are generally asymptomatic, though they may have minimally reduced β‑enolase activity without clinical consequences, analogous to carrier states in other recessive metabolic myopathies.[3][8][16] Family history of muscle enolase deficiency or consanguinity increases the probability of biallelic inheritance in offspring, and thus represents a genetic risk factor.

At the population level, ENO3 missense variants such as c.467G>A (p.Gly156Asp) are present at very low allele frequencies in gnomAD and similar databases (approximately 0.03%), indicating that carrier status is rare but not negligible.[16] There is currently no evidence for specific ethnic or geographic clustering of ENO3 pathogenic variants, nor for founder mutations in particular populations, although the limited number of reported cases (Italy, United Kingdom, and possibly other European origins) suggests that European ancestry may be represented among early patients.[3][4][8][11][17] More detailed population genetics data are lacking.

Environmental risk factors predominantly relate to behavior and lifestyle. Intense anaerobic exercise, participation in high‑intensity sports without adequate conditioning, and activities requiring repeated maximal effort (such as sprinting, weightlifting, or military training) pose increased risk of symptomatic episodes and rhabdomyolysis in individuals with GSD XIII.[2][3][4][5][11][17] Dehydration, heat stress, and concomitant use of medications that may predispose to muscle injury (for example, statins or certain antipsychotics) could theoretically increase risk, though such interactions have not been systematically studied in GSD XIII.

Sex, age, and body composition may also influence risk. Reported patients have been adults, often middle‑aged at first presentation, suggesting that cumulative exposure to strenuous activity or age‑related changes in muscle physiology may modulate manifestation.[3][4][5][8][11] There is no clear evidence of sex predilection, but most published cases involve males; this may reflect referral bias rather than true biological difference.[3][4][8][11][17] Obesity or low physical conditioning could exacerbate exertional symptoms, as in other metabolic myopathies, though data specific to GSD XIII are not available.

2.4 Protective Factors and Modifiers of Disease Severity

Protective factors for GSD XIII can be conceptualized at several levels. At the genetic level, residual β‑enolase activity appears to mitigate disease severity. IAMGSD notes that patients with GSD XIII may be less affected than those with McArdle disease (GSD V), and that milder symptoms could be due to some residual enzyme activity, described as approximately 10–20% in reported cases.[11] In contrast, the index patient had only 5% residual activity and experienced significant exercise intolerance and myalgias, though no rhabdomyolysis, suggesting a gradient of severity with enzyme activity.[3] Variants that partially disrupt protein stability or catalytic function, rather than completely abolishing activity, may therefore confer a milder phenotype and act as genetic modifiers of disease severity.

At the behavioral level, avoidance of intense anaerobic exercise is a key protective factor. IAMGSD emphasizes that the outlook for patients is good with avoidance of intense exercise, and recommends following similar precautions to those used in McArdle disease to prevent rhabdomyolysis.[11] Tarnopolsky’s review similarly underscores that therapy for glycogen storage diseases that result in exercise‑induced symptoms includes lifestyle adaptation and carefully titrated exercise programs, which can reduce the risk of episodes while maintaining overall fitness.[2] Engaging primarily in moderate, aerobic exercise with appropriate warm‑up and cool‑down, maintaining hydration, and avoiding sudden maximal efforts are likely protective strategies in GSD XIII, as they are in other glycolytic myopathies.[2]

Environmental and nutritional factors may also modulate severity. Pre‑exercise carbohydrate ingestion can sometimes ameliorate symptoms in some metabolic myopathies by providing alternative energy sources, though the benefit in distal glycolytic defects like β‑enolase deficiency is less clear than in upstream glycogenolysis disorders.[2] Adequate hydration and immediate cessation of activity at the onset of muscle pain can prevent progression to rhabdomyolysis. No specific dietary protective factor has been systematically studied in GSD XIII, and there are no known pharmacologic agents that increase β‑enolase activity.

2.5 Gene–Environment Interactions

GSD XIII exemplifies a classic gene–environment interaction in metabolic myopathies: ENO3 mutations create a fixed enzymatic defect, but clinical expression depends strongly on environmental and behavioral stressors, particularly exercise.[2][3][4][5][8][11][17] In resting conditions and with low‑intensity activity, affected individuals may remain asymptomatic, because oxidative metabolism and residual glycolytic activity suffice to meet energy demands. However, during abrupt high‑intensity exercise requiring rapid ATP generation via anaerobic glycolysis, the β‑enolase deficiency imposes a bottleneck at the 2‑phosphoglycerate to phosphoenolpyruvate step, preventing adequate ATP production and leading to failure of muscle contraction, pain, and eventual muscle fiber damage.[2][3][17]

The ischemic forearm exercise test in the index patient illustrated this interaction: during forearm exercise under ischemic conditions (blood flow occlusion), there was no rise in serum lactate, indicating impaired glycolytic flux, while the patient experienced myalgias and fatigue.[3] This failure to generate lactate despite intense muscular activity underscores the inability of the mutated ENO3 enzyme to respond to environmental demands. Similar patterns likely occur during whole‑body exertion. Toscano et al.’s study of exercise metabolism in β‑enolase deficiency was designed precisely to characterize these gene–environment interactions, although detailed findings are beyond the provided snippet.[17]

From a mechanistic perspective, the interaction can be described using Gene Ontology (GO) and Cell Ontology (CL) concepts. ENO3 is involved in the glycolytic process (GO:0006096) and carbohydrate metabolic process (GO:0005975) in skeletal muscle cells (CL:0000182), and environmental stimuli such as exercise alter the demand for these processes. When ENO3 function is compromised, the homeostatic response to environmental stress fails, leading to disease phenotypes. This illustrates how genetic variants and environmental exposures jointly shape disease expression in inborn errors of metabolism.

3. Phenotypes: Clinical, Laboratory, and Quality of Life Features

3.1 Core Neuromuscular Phenotypes

The core clinical phenotype of GSD XIII consists of exercise intolerance, myalgia, and muscle weakness that manifest predominantly during or after exertion.[2][3][4][5][10][11] Tarnopolsky’s review lists “exercise intolerance” and “rhabdomyolysis” as main features of GSD XIII.[2] Orphanet describes “exercise intolerance and myalgia” as defining clinical manifestations.[5] Metagene enumerates exercise intolerance, exertion intolerance, muscle cramps, muscle weakness, and pain, with adult onset.[4] IAMGSD highlights muscle pain and fatigue during intense activity as the primary symptoms, noting that baseline CK may be normal and that rhabdomyolysis can occur.[11] Malacards summarizes that the disease is characterized by exercise‑induced myalgias, generalized muscle weakness, and fatigability.[10]

The index patient reported by Comi et al. was a 47‑year‑old man affected with exercise intolerance and myalgias, without episodes of frank rhabdomyolysis but with significant limitation in physical performance.[3] During ischemic forearm exercise, he experienced pain and fatigue, with no rise in lactate.[3] Muscle weakness in GSD XIII tends to be functional and exertional rather than severe baseline paresis; patients may have near‑normal strength at rest but exhibit rapid fatigability and difficulty sustaining effort.[2][3][4][11] The distribution of weakness is generally generalized or proximal, involving major skeletal muscle groups engaged in exercise.

Suggested Human Phenotype Ontology (HPO) terms for these core neuromuscular features include Exercise intolerance (HP:0003546 or HP:0009052, depending on granularity), Muscle pain or Myalgia (HP:0003326), Muscle weakness (HP:0001324 or HP:0004324), Fatigability (HP:0003405), and Muscle cramp (HP:0003413). These terms capture the subjective symptoms and objective signs observed in patients with GSD XIII. The age of onset for these phenotypes is primarily adolescence or adulthood, with Orphanet specifying adult onset and IAMGSD noting early and adult onset but emphasizing adult presentations.[4][5][11] Severity appears mild to moderate in daily life but can be severe during episodes, particularly when rhabdomyolysis occurs.[2][3][4][11] The course is episodic and exertion‑dependent, with symptoms fluctuating according to physical activity rather than progressive neurodegeneration.

In terms of quality of life, exercise intolerance and myalgia significantly affect participation in sports, occupational tasks requiring physical effort, and activities of daily living that involve climbing stairs, carrying loads, or prolonged walking. Patients may adapt by avoiding strenuous activities, which can in turn limit social participation and contribute to reduced physical fitness. No formal SF‑36 or EQ‑5D studies have been conducted specifically in GSD XIII, but extrapolation from other metabolic myopathies suggests impairments in physical functioning, vitality, and role‑physical domains, with relatively preserved mental health.[2]

3.2 Laboratory and Metabolic Abnormalities

Laboratory abnormalities in GSD XIII reflect muscle damage during episodes and impaired glycolytic response to exercise, rather than chronic, static derangements. Serum creatine kinase (CK) may be normal at baseline but is often elevated following exertional episodes, particularly when rhabdomyolysis occurs.[2][4][11] Tarnopolsky notes that serum CK is often elevated in myopathic forms of glycogen metabolism disorders, including PYGM deficiency, but can be normal and increase only with rhabdomyolysis in disorders such as PGAM2, PFK, and ENO3.[2] Metagene lists “Creatine kinase inc (serum)” as a laboratory finding in GSD XIII.[4] IAMGSD similarly reports normal baseline CK with elevations during episodes.[11]

Myoglobinuria is a consequence of rhabdomyolysis and is noted in Metagene as “Myoglobin inc (urine)” and in IAMGSD as a secondary feature.[4][11] This can present clinically as dark or cola‑colored urine after intense exercise and represents a risk factor for acute kidney injury. Elevated serum myoglobin and other markers of muscle breakdown are expected during rhabdomyolysis episodes, although specific values have not been systematically reported in the limited case literature.

A distinctive metabolic abnormality in GSD XIII is the failure to increase lactate during ischemic or intense exercise. In the index case, no rise of serum lactate was observed during the ischemic forearm test, consistent with a block in distal glycolysis.[3] This contrasts with normal lactate responses in healthy individuals and with specific patterns in other metabolic myopathies. For example, in McArdle disease (myophosphorylase deficiency), lactate levels also fail to rise because glycogenolysis is impaired upstream.[2] In distal glycolytic defects such as PFK or PGAM2 deficiency, lactate abnormalities reflect the specific step affected.[2] In GSD XIII, the block at enolase prevents conversion of 2‑phosphoglycerate to phosphoenolpyruvate, thereby impeding substrate availability for pyruvate and subsequent lactate production.[2][3]

Muscle biopsy reveals increased glycogen content and ultrastructural changes. Metagene reports “Glycogen inc (muscle)” as a laboratory finding in GSD XIII.[4] Comi et al. described “focal sarcoplasmic accumulation of glycogen beta particles” on electron microscopy, indicating localized glycogen storage.[3] β‑enolase activity measured in muscle homogenates is markedly reduced, with approximately 5% residual activity in the index patient and 10–20% in other reported cases.[3][4][11] These laboratory findings provide biochemical confirmation of the ENO3 deficiency.

Suggested HPO terms for laboratory abnormalities include Elevated serum creatine kinase (HP:0001713), Myoglobinuria (HP:0002886), Abnormal muscle glycogen content (HP:0008951), Abnormal lactate response to exercise (HP:0005977), and Rhabdomyolysis (HP:0003201). The onset of laboratory abnormalities coincides with symptomatic episodes, making them episodic and event‑related rather than chronic.

3.3 Episodic Phenotypes: Rhabdomyolysis and Myoglobinuria

Rhabdomyolysis and myoglobinuria are important episodic phenotypes in GSD XIII, reflecting acute muscle breakdown triggered by intense exercise.[2][4][10][11] Metagene lists rhabdomyolysis among the symptoms of ENO3 deficiency, stating that the disease is characterized by exercise intolerance, muscle cramps, muscle weakness, pain, and rhabdomyolysis, with myoglobinuria as a laboratory finding.[4] IAMGSD notes that patients can experience rhabdomyolysis and myoglobinuria, and that these episodes are less frequent or severe than in McArdle disease but nonetheless clinically significant.[11] Tarnopolsky’s review emphasizes that many glycogen metabolism disorders, including GSD XIII, present with rhabdomyolysis induced by exercise or other stressors.[2]

The onset of rhabdomyolysis episodes is typically in adolescence or adulthood, coinciding with periods of intense physical training or unaccustomed exertion. Severity can range from mild, self‑limited episodes with transient CK elevation to severe rhabdomyolysis with dramatically increased CK, myoglobinuria, muscle pain, and risk of acute kidney injury. Frequency appears variable but likely low in GSD XIII compared to McArdle disease, due in part to residual β‑enolase activity and adaptation behaviors.[2][4][11] The progression of episodes is acute and self‑limited with appropriate rest and hydration, but recurrent episodes can lead to chronic muscle damage if prevention strategies are not implemented.

Suggested HPO terms include Rhabdomyolysis (HP:0003201) and Myoglobinuria (HP:0002886), and, where kidney involvement occurs, Acute kidney injury (HP:0001919). These phenotypes significantly impact quality of life by necessitating emergency medical evaluation and temporary impairment of mobility and function. They also influence psychological well‑being due to fear of recurrence and limitations on physical activity. No formal quality of life instruments have been applied specifically to rhabdomyolysis in GSD XIII, but the general impact is consistent with other exertional rhabdomyolysis disorders.

3.4 Muscle Pathology and Structural Phenotypes

Structural phenotypes in muscle are revealed by biopsy and ultrastructural analysis rather than clinical observation. Comi et al. reported focal sarcoplasmic accumulation of glycogen β particles and severe reduction of β‑enolase protein on immunohistochemistry and immunoblotting, with normal representation of α‑enolase.[3] Muscle fibers may display mild myopathic changes, such as variation in fiber size and minimal necrosis, but no specific histopathologic signature beyond glycogen accumulation and enzyme deficiency has been uniquely associated with GSD XIII.[2][3][4]

Metagene’s summary of laboratory findings includes decreased β‑enolase in muscle and increased glycogen.[4] This aligns with Tarnopolsky’s description of glycogen metabolism disorders, where muscle biopsies often show increased glycogen, vacuolar changes, and enzyme deficiencies detectable by histochemistry and immunostaining.[2] In GSD XIII, the absence of β‑enolase staining with preservation of other glycolytic enzymes provides both diagnostic specificity and mechanistic insight.

Suggested HPO terms for structural phenotypes include Abnormal muscle morphology (HP:0004305), Abnormal skeletal muscle fiber morphology (HP:0004306), and Abnormal glycogen storage in muscle tissue (HP:0008951). These features are static and reflect the underlying biochemical defect rather than dynamic episodes. Their impact on quality of life is indirect, primarily through functional consequences.

3.5 Phenotype Summary Table and Ontology Mapping

To integrate clinical and laboratory phenotypes, the following table summarizes key features of GSD XIII and suggested ontology mappings. The frequencies are qualitative due to the small number of reported patients.

This table provides a structured mapping of disease features to HPO terms, which can support computational phenotyping and integration into disease‑ontology‑based knowledge bases.

4. Genetic and Molecular Information

4.1 The ENO3 Gene: Structure, Expression, and Function

The ENO3 gene encodes enolase 3 (beta, muscle), one of three enolase isoenzymes present in mammals.[2][3][14][15] ENO3 is located on chromosome 17p13.2, with NCBI Gene ID 2027, HGNC symbol ENO3, and alternative names including muscle specific enolase, muscle enriched enolase, skeletal muscle enolase, and muscle‑specific enolase (MSE).[14][15] It is a protein‑coding gene with multiple alternatively spliced transcript variants, reflecting complex regulation and potential tissue‑specific isoforms.[14][15]

Enolase is a glycolytic enzyme that catalyzes the reversible dehydration of 2‑phosphoglycerate to phosphoenolpyruvate, an essential step in glycolysis.[2][3] The β‑enolase subunit encoded by ENO3 is predominantly expressed in skeletal muscle and heart, where it constitutes the majority of enolase activity in adults.[3][14] A developmental switch from α‑enolase to β‑enolase occurs in muscle tissue during development in rodents, and similar patterns are inferred in humans, suggesting that ENO3 plays a role in muscle development and regeneration as well as mature function.[14]

Expression data from NCBI indicate biased expression of ENO3 in heart (RPKM 88.5), esophagus (RPKM 45.6), and several other tissues, with particularly high levels in skeletal muscle.[14] This expression pattern explains the tissue specificity of GSD XIII: despite the ubiquitous presence of glycolysis in many tissues, the severe reduction of β‑enolase due to ENO3 mutations predominantly affects skeletal muscle, where other enolase isoforms cannot fully compensate.[3][14] In contrast, α‑enolase (ENO1) and γ‑enolase (ENO2) have distinct expression profiles, with ENO1 being more ubiquitous and ENO2 being primarily neuronal.[2][10][14]

At the protein level, β‑enolase is annotated in UniProt and related databases with catalytic activity in the glycolytic process (GO:0006096), binding to substrates 2‑phosphoglycerate and phosphoenolpyruvate, and potential interactions with cytoskeletal structures in muscle fibers. The enzyme functions as a dimer, with active sites contributed by both subunits. Mutations that alter residues near the catalytic site or dimer interface can reduce enzymatic activity, destabilize protein structure, or impair localization, leading to loss‑of‑function phenotypes.[3][16]

4.2 Pathogenic Variants: Types, Functional Consequences, and Frequencies

To date, only a small number of ENO3 variants have been clearly implicated in GSD XIII. Comi et al. identified two missense mutations in the index patient: c.467G>A (p.Gly156Asp) and c.1121G>A (p.Gly374Glu).[3][16] Gly156 is a highly conserved residue located near the catalytic site; substitution to aspartic acid introduces a charged side chain that likely disrupts local structure and catalytic efficiency.[3][16] Gly374 is also conserved, and substitution to glutamic acid may affect stability and folding. Functional studies reported by Comi et al. and subsequent experimental work suggest that these mutations result in decreased stability of mutant β‑enolase and markedly reduced enzyme activity in muscle, with residual activity around 5%.[3][16]

ClinVar records the c.467G>A (p.Gly156Asp) variant as associated with “Glycogen storage disease due to muscle beta‑enolase deficiency,” noting that experimental studies (PMID:18070103, as referenced by ClinVar) have shown that this missense change affects ENO3 function and that advanced structural modeling predicts disruption of protein function.[16] The variant is present in population databases (rs121918403, gnomAD ~0.03%), indicating that heterozygous carriers exist at low frequency.[16] However, due to limited case numbers and uncertain penetrance, ClinVar currently classifies this variant as a Variant of Uncertain Significance (VUS), emphasizing that more data are needed to fully establish pathogenicity.[16] This classification reflects the tension between strong functional evidence and limited clinical observations, which is common in ultra‑rare diseases.

Other ENO3 variants associated with GSD XIII have been reported by Wigley et al. (2019) in JIMD Reports, where ENO3 variants identified by genomic sequencing were confirmed functionally by enzyme assays.[8] While the specific variant details are not visible in the provided snippet, the authors’ conclusion that biochemical testing remains essential indicates that multiple missense variants can reduce β‑enolase activity sufficiently to cause disease.[8] Toscano et al. (2021) studied energy metabolism in patients with β‑enolase deficiency, implying additional genotypes; however, their variants may similarly be missense or other loss‑of‑function alleles.[17]

Metagene and Malacards summarize that GSD XIII is caused by autosomal recessive ENO3 mutations, primarily missense variants affecting highly conserved residues.[4][10] No nonsense, frameshift, or large deletions have been definitively reported in human patients, but such variants would be expected to cause severe loss of β‑enolase function and could be embryonically or neonatally lethal or compensated by other isoforms. Somatic ENO3 mutations are not implicated in the disease, and there is no evidence for structural chromosomal abnormalities involving ENO3.[14][15][16]

The functional consequence of pathogenic ENO3 variants is loss of function, characterized by decreased stability, reduced catalytic activity, and lower protein levels in skeletal muscle.[3][16] This leads to the biochemical phenotype of severe β‑enolase deficiency and the clinical features of exercise intolerance and rhabdomyolysis. From an ACMG/AMP perspective, these variants are supported by functional (PS3), computational (PP3), and case‑level (PS4) evidence, but lack extensive segregation or population data, constraining their classification.

4.3 Isoenzyme Context and Modifier Genes

Enolase exists as three main isoforms in mammals: α‑enolase (ENO1), β‑enolase (ENO3), and γ‑enolase (ENO2). ENO1 is ubiquitous and also serves as the structural gene for the plasminogen receptor on the cell surface; ENO2 is neuron‑specific and associated with neuronal markers; ENO3 is muscle‑specific.[2][10][14] In skeletal muscle, β‑enolase is predominant, but α‑enolase is also present. The index patient with GSD XIII had dramatically reduced β‑enolase protein in muscle, with normal α‑enolase, indicating that α‑enolase cannot fully compensate for the loss of β‑enolase under high‑demand conditions.[3]

Malacards notes that enolase deficiency can occur in red blood cells due to ENO1 mutations, leading to hemolytic anemia and a spherocytic phenotype, with autosomal dominant inheritance.[10] This represents a distinct enolase‑related disease, illustrating the isoenzyme‑specific manifestations of enolase gene mutations. It also suggests that ENO1 and ENO2 could, in theory, act as modifier genes for ENO3‑related disease, but no such interactions have been reported. The presence of α‑enolase in muscle likely provides baseline glycolytic capacity, but cannot match the high flux required during intense exercise, leading to the exertional phenotype in GSD XIII.

No specific modifier genes have been identified that alter the severity of GSD XIII. Variants in other glycolytic enzymes or in regulators of muscle metabolism could theoretically modulate symptoms, but, given the limited number of patients, such interactions have not been studied. Epigenetic regulation of ENO3 expression, for example through DNA methylation or histone modifications, might influence residual activity or disease onset, but there are no data on epigenetic changes in GSD XIII.[14][15] Therefore, current knowledge focuses on ENO3 as the primary causal gene, with isoenzyme context explaining tissue specificity.

4.4 Epigenetic Information and Genomic Structural Features

As noted, epigenetic information specific to ENO3 in GSD XIII has not been reported. ENO3 expression is tissue‑specific and developmentally regulated, suggesting that epigenetic mechanisms contribute to its normal regulation, but disease‑associated epigenetic changes have not been identified.[14][15] No genome‑wide epigenomic studies have been conducted in patients with GSD XIII, and single‑cell or spatial transcriptomics analyses are unavailable.

Structural genomic features of ENO3 include its location on 17p13.2 between other metabolic genes, with a defined exon–intron structure and multiple transcripts, as visualized in the UCSC Genome Browser.[15] No structural variants such as deletions, duplications, or translocations involving ENO3 have been linked to GSD XIII in DECIPHER, dbVar, or similar databases. The disease is thus primarily a sequence variant‑driven monogenic disorder, with structural and epigenetic genomic features remaining background rather than causal.

5. Environmental Information

5.1 Environmental Factors and Exposures

There is no evidence that specific environmental toxins, pollutants, or radiation directly cause muscle β‑enolase deficiency. Comparative toxicogenomics databases and occupational health literature have not reported associations between particular chemicals and ENO3‑related disease. GSD XIII is consistently described as a genetic, autosomal recessive disorder, and all known cases involve ENO3 variants.[3][4][5][8][10][11][12][16][17]

Nevertheless, environmental factors – broadly defined – play important roles as triggers of symptomatic episodes. The most salient environmental factor is physical exercise, particularly intense, anaerobic, and unaccustomed exertion. This includes activities such as sprinting, heavy weightlifting, high‑intensity interval training, and military drills, which require rapid ATP production via glycolysis and impose high demands on skeletal muscle energy metabolism.[2][3][4][11][17] Heat, humidity, altitude, and other environmental conditions that increase metabolic stress can exacerbate symptoms and increase the likelihood of rhabdomyolysis.

Other potential environmental contributors include dehydration, which reduces perfusion and increases susceptibility to muscle injury, and systemic illness or infection, which can trigger catabolic states that stress muscle metabolism.[2] Medications with known myotoxic potential, such as statins, fibrates, or certain antipsychotics, could theoretically interact with underlying metabolic myopathy to increase risk of muscle symptoms, although specific cases have not been reported in GSD XIII.

5.2 Lifestyle Factors: Diet, Exercise, and Habits

Lifestyle factors are centrally important in GSD XIII because they determine exposure to exercise stress and modulate disease expression. Patients with GSD XIII often learn, consciously or unconsciously, to avoid activities that precipitate symptoms, leading to self‑selected reductions in high‑intensity exercise.[3][4][11] IAMGSD explicitly recommends avoidance of anaerobic activity and notes that the outlook is good with adherence to this strategy.[11] Tarnopolsky discusses lifestyle adaptation and carefully titrated exercise programs as key components of therapy for glycogen storage diseases with exercise‑induced symptoms, including β‑enolase deficiency.[2]

Diet may influence symptom severity, though specific data for GSD XIII are lacking. Adequate carbohydrate intake and maintenance of normal blood glucose levels support energy metabolism; however, since β‑enolase functions downstream of glucose utilization, simple carbohydrate loading may not fully bypass the defect. In other metabolic myopathies, strategies such as sucrose ingestion before exercise or high‑protein diets have been explored.[2] In GSD XIII, moderate evidence suggests that consistent aerobic conditioning with gradual progression may improve overall fitness and reduce susceptibility to symptoms, but randomized trials are unavailable.

Habits such as smoking, excessive alcohol consumption, and sedentary lifestyle can indirectly affect muscle health and cardiovascular function, but their specific impact on β‑enolase deficiency has not been studied. General health recommendations (smoking cessation, moderate alcohol use, regular moderate exercise) remain applicable.

5.3 Infectious Agents

No infectious agents are known to cause GSD XIII or directly alter ENO3 function. Infections may serve as metabolic stressors, precipitating rhabdomyolysis in susceptible individuals via fever, systemic inflammation, or catabolic state, as observed in other metabolic myopathies.[2] For example, viral infections such as influenza can cause rhabdomyolysis in general, and in patients with underlying metabolic defects, these episodes may be more frequent or severe. However, specific case reports linking infection to rhabdomyolysis in GSD XIII have not been documented.

6. Mechanism and Pathophysiology

6.1 Normal Skeletal Muscle Glycolysis and Glycogen Metabolism

Understanding GSD XIII requires an appreciation of normal skeletal muscle glycolysis and glycogen metabolism. In skeletal muscle, ATP is generated through three main pathways: phosphagen (creatine kinase), glycolysis (anaerobic), and oxidative phosphorylation (aerobic). During high‑intensity, short‑duration exercise, anaerobic glycolysis dominates, rapidly generating ATP from glucose or glycogen without requiring oxygen.[2]

Glycolysis consists of a sequence of enzymatic steps converting glucose to pyruvate, with several branch points and regulatory controls. In muscle, glucose is derived from blood or from glycogen stored in myofibers. Glycogenolysis, mediated by myophosphorylase (PYGM), converts glycogen to glucose‑1‑phosphate, which is then converted to glucose‑6‑phosphate and enters glycolysis.[2] Early steps of glycolysis involve hexokinase and phosphofructokinase (PFK), followed by aldolase A (ALDOA), phosphoglycerate mutase (PGAM2), and then enolase (ENO3) in the distal part of the pathway. Enolase catalyzes the interconversion of 2‑phosphoglycerate and phosphoenolpyruvate, which is then converted to pyruvate by pyruvate kinase.[2][3]

The resulting pyruvate can either be reduced to lactate by lactate dehydrogenase in anaerobic conditions or transported into mitochondria for oxidative metabolism. The production of lactate allows regeneration of NAD(^+), sustaining glycolytic flux. In intense exercise, skeletal muscle relies heavily on this glycolytic cascade, and any enzymatic defect can impair ATP generation and lead to muscle fatigue and injury.[2]

In addition to energy production, glycogen and glycolysis play roles in muscle development and regeneration, as ENO3 expression increases during differentiation and supports metabolic demands of growing fibers.[14] Therefore, ENO3 and β‑enolase are integral to both acute energy metabolism and long‑term muscle physiology.

6.2 Distal Glycolytic Block due to β‑Enolase Deficiency

In GSD XIII, mutations in ENO3 lead to severe deficiency of β‑enolase in skeletal muscle, creating a distal glycolytic block at the 2‑phosphoglycerate to phosphoenolpyruvate step.[2][3][4][5] As a result, high‑flux glycolysis during intense exercise is compromised, and the cascade from glycogen to lactate cannot proceed efficiently. This has several consequences.

First, ATP generation via glycolysis is reduced, particularly under conditions where oxidative phosphorylation cannot fully meet demand (such as ischemic or very high‑intensity exercise). Skeletal muscle fibers are unable to sustain contractile activity, leading to early fatigue and functional weakness.[2][3][17] Second, lactate production is impaired, as evidenced by the absent rise in serum lactate during ischemic forearm exercise in the index patient.[3] This distinguishes β‑enolase deficiency from some other metabolic myopathies with normal lactate responses.

Third, upstream glycolytic intermediates and glycogen can accumulate. Comi et al. reported focal sarcoplasmic accumulation of glycogen β particles in muscle, and Metagene notes increased glycogen content.[3][4] Although GSD XIII is categorized among glycogen storage diseases, the primary defect is in glycolysis, and glycogen accumulation is secondary to reduced downstream flux. This accumulation may be modest compared to classic glycogen storage diseases such as McArdle disease or Pompe disease.[2]

At the molecular level, mutant β‑enolase proteins exhibit decreased stability, are degraded more rapidly, or fail to dimerize properly, leading to reduced enzyme activity.[3][16] Structural modeling indicates that substitutions at conserved glycine residues near the catalytic site disrupt local folding and active site configuration, undermining catalytic efficiency.[16] The residual presence of α‑enolase in muscle provides some basal glycolytic capacity, but cannot compensate fully for loss of β‑enolase under high‑demand conditions, given the expression pattern and kinetic properties.[3][14]

6.3 Causal Chain from ENO3 Mutation to Clinical Manifestation

The pathophysiological causal chain in GSD XIII can be described stepwise, integrating genetic, molecular, cellular, tissue, and clinical levels.

At the genetic level, individuals inherit biallelic ENO3 variants (missense mutations) in an autosomal recessive pattern.[3][16] These variants encode mutant β‑enolase proteins with decreased stability and catalytic activity, leading to a loss‑of‑function phenotype.[3][16]

At the protein and cellular level, skeletal muscle fibers exhibit severely reduced β‑enolase activity. Enzyme assays show residual activities of approximately 5–20% of normal, depending on the variant and individual.[3][4][11] The glycolytic process (GO:0006096) is impaired in muscle cells (CL:0000182), especially during high‑demand conditions. Under resting or low‑intensity activity, oxidative metabolism and residual glycolysis suffice, and ATP levels remain adequate. Under intense exercise, however, the defective enolase step cannot generate sufficient phosphoenolpyruvate, leading to reduced pyruvate and lactate, impaired NAD(^+) regeneration, and failure to sustain glycolysis.[2][3][17]

At the tissue level, skeletal muscle fibers subjected to high workload undergo energy crisis. ATP depletion and ionic imbalance lead to failure of excitation–contraction coupling, causing early fatigue and subjective weakness. Prolonged or extreme exertion causes membrane instability, calcium influx, and activation of proteolytic pathways, culminating in muscle fiber necrosis and rhabdomyolysis.[2] Intracellular contents, including CK and myoglobin, are released into the circulation, and myoglobin is filtered by the kidneys, producing myoglobinuria and risking acute tubular necrosis.[2][4][11]

At the organ and clinical level, patients experience exercise intolerance, myalgia, and muscle weakness during exertion, and occasionally rhabdomyolysis with myoglobinuria and systemic symptoms (fatigue, malaise, dark urine).[2][3][4][11] Episodes are triggered by environmental stimuli (exercise, heat, dehydration) interacting with the fixed genetic defect. Muscle biopsy shows increased glycogen and reduced β‑enolase, providing diagnostic evidence.[3][4] Over time, repeated episodes may cause chronic muscle damage, but in reported cases the overall course appears relatively stable, with adaptation via lifestyle modification.[2][4][11]

This causal chain illustrates upstream (genetic and molecular) mechanisms leading to downstream (tissue and clinical) manifestations. The upstream defect is localized and static, while downstream events are episodic and environment‑dependent. GO terms such as response to exercise (GO:0043058), skeletal muscle contraction (GO:0003009), and regulation of glycolytic process (GO:0006110) can be applied to describe the biological processes interconnecting these levels. CL terms such as skeletal muscle fiber (CL:0000182) and myoblast (CL:0000056) denote the cell types involved.

6.4 Comparison with Other Glycogen and Glycolysis Disorders

Comparative analysis of GSD XIII with other glycogen and glycolysis disorders clarifies its unique features. Tarnopolsky’s table of glycogen metabolism disorders lists multiple enzymes: myophosphorylase (PYGM, GSD V), glycogen debranching enzyme (AGL, GSD III), phosphorylase b kinase (PHKB), phosphofructokinase (PFK, Tarui disease), phosphoglycerate mutase (PGAM2), aldolase A (ALDOA), β‑enolase (ENO3, GSD XIII), and others.[2]

In McArdle disease (GSD V), the defect lies in glycogenolysis; patients cannot mobilize glycogen to glucose‑1‑phosphate, leading to severe exercise intolerance, early fatigue, muscle pain, and frequent rhabdomyolysis, with absent lactate rise in exercise tests.[2] GSD XIII shares exercise intolerance and absent lactate rise but has a distal glycolytic block rather than an upstream glycogenolytic block, and often milder chronic symptoms.[2][3][4][11]

In Tarui disease (PFK deficiency), the defect occurs earlier in glycolysis; patients have exercise intolerance and hemolytic anemia due to PFK expression in red blood cells.[2] GSD XIII lacks hematologic manifestations, reflecting the muscle‑specific expression of ENO3. In PGAM2 deficiency, an intermediate step is affected, producing exercise intolerance and myoglobinuria; ENO3 deficiency lies downstream of PGAM2 in the pathway.[2]

These comparisons highlight that different enzymatic defects in glycogen and glycolysis yield overlapping but distinct clinical phenotypes depending on tissue expression and position in the pathway. GSD XIII stands out as a distal glycolytic defect limited to skeletal muscle, with relatively sparse glycogen accumulation and moderate severity.

7. Anatomical Structures Affected

7.1 Organ‑Level Involvement

The primary organ system affected by GSD XIII is the musculoskeletal system, specifically skeletal muscle. Orphanet and GARD classify the disease among muscle disorders, and IAMGSD notes that skeletal muscle is the involved tissue.[1][4][5][11] In anatomical ontology terms, the relevant organ is skeletal muscle organ (UBERON:0001134), encompassing appendicular and axial muscles.

Within skeletal muscle, major muscle groups engaged in exercise – such as thigh, calf, back, and arm muscles – are affected during exertion, with pain and weakness manifesting in these areas. There is no evidence of selective involvement of particular muscle groups beyond those commonly engaged in the activities that trigger symptoms.[2][3][4][11]

Secondary organ involvement can occur during rhabdomyolysis episodes. The kidneys (UBERON:0002113) are at risk due to myoglobinuria and potential acute tubular necrosis, leading to acute kidney injury.[2][4][11] The cardiovascular system may be indirectly stressed by systemic effects, but primary cardiac involvement has not been documented, despite ENO3 expression in heart.[14] The nervous system is not primarily affected; cognitive and central neurologic function remain intact, and there is no evidence of neuropathy or central nervous system disease attributable to ENO3 mutations.[2][3][5]

7.2 Tissue and Cell‑Level Involvement

At the tissue level, the primary affected tissue type is striated muscle tissue (UBERON:0002385), particularly in limb muscles. Within this tissue, the key cell type is the skeletal muscle fiber or skeletal muscle cell (Cell Ontology CL:0000182), which expresses ENO3 and relies on glycolysis for rapid ATP production.[14]

Muscle biopsy shows changes in these cells, including glycogen accumulation in the sarcoplasm and reduced β‑enolase staining.[3][4] Myoblasts and satellite cells (CL:0000056, CL:0000598) may also be affected in terms of energy metabolism and regenerative capacity, although specific data on regeneration after injury in GSD XIII are lacking. Other cell types in muscle (fibroblasts, endothelial cells) are not directly impacted by ENO3 deficiency, as they express different enolase isoforms.

During rhabdomyolysis, necrosis of muscle fibers leads to infiltration by immune cells (macrophages, neutrophils), but this is a generic response to muscle injury rather than a specific feature of ENO3 deficiency. The immune system does not appear to play a primary pathogenic role in GSD XIII.

7.3 Subcellular Compartments and Localization

At the subcellular level, β‑enolase localizes mainly in the cytosol (GO:0005829) of skeletal muscle cells, where glycolytic enzymes form multi‑enzyme complexes that may associate with cytoskeletal structures. Enolase functions as a soluble enzyme in the cytoplasmic compartment, interacting with substrates and co‑factors. ENO3 mutations likely impact cytosolic enzyme stability, leading to reduced protein levels detected by immunohistochemistry and immunoblotting.[3][16]

Glycogen accumulation occurs in the sarcoplasm, an intracellular compartment in muscle fibers where glycogen particles are normally stored. In GSD XIII, focal sarcoplasmic glycogen accumulation reflects altered metabolism and may affect local structural properties of the fibers.[3][4] Mitochondria (GO:0005739) remain structurally intact, and oxidative phosphorylation is not primarily impaired. The nucleus (GO:0005634) and other organelles show no specific abnormalities.

There is no lateralization or asymmetric involvement reported; the disease affects muscles bilaterally and symmetrically in relation to usage patterns. For example, running or walking affects leg muscles bilaterally; unilateral symptoms would more likely reflect localized injury rather than systemic metabolic defect.

8. Temporal Development and Natural History

8.1 Age of Onset and Onset Pattern

GSD XIII is characterized by adolescent or adult onset, with Orphanet specifying adult onset and IAMGSD noting both early and adult onset while emphasizing adult presentation.[4][5][11] The index patient described by Comi et al. was 47 years old at diagnosis, with symptoms having developed over years of exercise intolerance.[3] Other cases reported in Italy and the United Kingdom also involved adults at the time of diagnosis, though some may have traced symptoms back to adolescence.[4][8][11][17]

The onset pattern is typically chronic and insidious, with gradual recognition of exercise intolerance and myalgia during physical activity. Patients may initially attribute symptoms to deconditioning or aging and only seek medical attention when limitations become pronounced or when acute rhabdomyolysis occurs.[2][3][11] In some cases, onset may appear more acute, when a first severe rhabdomyolysis episode manifests during extreme exertion, revealing an underlying metabolic vulnerability. However, the underlying defect is present from birth; the timing of clinical onset reflects exposure to environmental triggers and developmental changes in muscle metabolism.

8.2 Progression, Disease Course, and Duration

The progression of GSD XIII is not fully characterized due to the small number of patients and lack of long‑term natural history studies. Available data suggest a relatively stable course, in which chronic exercise intolerance and myalgia persist but do not necessarily worsen dramatically over time, provided that lifestyle adaptations are implemented.[2][3][4][11] Tarnopolsky describes many glycogen metabolism disorders as having stable or slowly progressive course, and GSD XIII appears to align more with the stable phenotype, especially compared to more severe systemic disorders such as Pompe disease.[2]

Rhabdomyolysis episodes are episodic, occurring sporadically and triggered by intense exercise or other stressors. Their frequency can decrease with patient education and avoidance strategies. IAMGSD notes that the outlook is good with avoidance of intense exercise, implying that disease course can be favorably modified.[11] There is no evidence of progressive muscle wasting or severe disability in reported cases, although subtle declines in physical capacity may occur with age and repeated episodes.

The disease duration is lifelong, as the genetic defect is permanent. However, clinical expression may be limited to certain life stages, such as adolescence and early adulthood when high‑intensity activities are more frequent. In older age, reduced participation in strenuous exercise may diminish symptomatic episodes, though underlying metabolic limitations persist.

8.3 Remission Patterns and Critical Periods

Spontaneous remission of GSD XIII does not occur, as the underlying genetic defect remains. However, functional remission – defined as periods with minimal or no symptoms – can occur when patients avoid triggers, engage in moderate exercise, and adhere to preventive strategies. Rhabdomyolysis episodes resolve with appropriate acute care, and long intervals between episodes may be regarded as remission periods.

Critical periods for intervention include adolescence and early adulthood, when individuals may first experience symptoms and high‑intensity activities are common. Early diagnosis and counseling can prevent severe rhabdomyolysis and guide safe exercise regimens. Another critical period is after an initial rhabdomyolysis episode: prompt recognition of the underlying metabolic cause and appropriate management can prevent recurrent episodes and renal complications.[2][11]

9. Inheritance, Epidemiology, and Population Characteristics

9.1 Inheritance Pattern, Penetrance, and Expressivity

GSD XIII follows an autosomal recessive inheritance pattern, as documented in Orphanet, GARD, OMIM, and ClinVar.[3][4][5][10][12][16] Biallelic ENO3 variants (homozygous or compound heterozygous) are required to manifest disease, with heterozygous carriers generally asymptomatic.[3][16] The index case and family studies showed segregation consistent with recessive inheritance: the patient was compound heterozygous, the mother and sister were heterozygous carriers, and other family members did not carry both variants.[3][16]

Penetrance among individuals with biallelic ENO3 variants appears high, as severe β‑enolase deficiency in muscle is expected to cause exercise intolerance and related symptoms. However, precise penetrance estimates are impossible due to the paucity of cases and potential underdiagnosis. Expressivity is likely variable, modulated by residual enzyme activity, lifestyle factors, conditioning, and perhaps other genetic modifiers. IAMGSD notes that patients may be less affected than those with McArdle disease, suggesting variability in symptom severity.[11]

There is no indication of genetic anticipation, as ENO3 mutations are not repeat expansions and do not show progressive worsening across generations. Germline mosaicism has not been reported. Consanguinity may increase risk in populations with high rates of consanguineous marriage, but specific data are absent.

9.2 Epidemiology: Prevalence and Incidence

GSD XIII is classified as an ultra‑rare disease. Orphanet estimates a prevalence of less than 1 per 1,000,000, reflecting its extremely low frequency in the population.[5] Malacards similarly notes a point prevalence of <1/1000000 worldwide, and Metagene reports that it is “very rare (3 cases).”[4][10] MONDO notes that muscle β‑enolase deficiency has been reported in one patient to date, but this likely refers to earlier data before additional cases were described.[6]

The true incidence is unknown, but given the rarity of reported cases and the gene’s carrier frequency, new cases may emerge sporadically. Underdiagnosis is possible, as mild exercise intolerance may be attributed to other causes and rhabdomyolysis episodes may not be fully investigated. Nevertheless, even accounting for underdiagnosis, GSD XIII remains among the rarest glycogen or glycolysis disorders.

9.3 Population Demographics, Geographic Distribution, and Sex Ratio

Published cases of GSD XIII have originated from Italy and the United Kingdom, suggesting European ancestry, though broader geographic representation is possible.[3][4][8][11][17] Orphanet and Malacards do not list specific regions of endemicity or ethnic predilections.[5][10] ENO3 variants such as c.467G>A are present at low frequency in global allele databases (gnomAD), indicating that carriers exist in multiple populations.[16] There is no evidence of founder mutations in particular populations.

Sex ratio is not clearly defined; early reports involve male patients, but the small sample size precludes conclusions. Expression in females may be similar, given autosomal recessive inheritance. Age distribution includes adolescents and adults, with index cases in middle age.[3][4][5][8][11]

Carrier frequency for specific ENO3 variants is extremely low (e.g., 0.03% for c.467G>A), leading to a very low probability of biallelic inheritance absent consanguinity or coincidental mating.[16] Therefore, GSD XIII is likely to remain rare even as genomic sequencing becomes more widespread.

10. Diagnostics

10.1 Clinical Evaluation and Suspicion

Diagnosis of GSD XIII begins with recognition of a compatible clinical picture: exercise‑induced myalgia, exercise intolerance, and episodic rhabdomyolysis in an otherwise healthy adolescent or adult, with normal baseline CK and no evidence of structural myopathy or neuropathy.[2][3][4][10][11] Clinicians should suspect a metabolic myopathy, particularly a glycogen or glycolysis disorder, when patients report early fatigue during exercise, inability to perform high‑intensity activity, and muscle pain after exertion.

A detailed history of exercise patterns, trigger activities, and family history is essential. Physical examination may be normal at rest, with normal strength and reflexes, or show subtle fatigability. Neurologic examination typically lacks signs of peripheral neuropathy or central involvement. Systemic examination may reveal signs of rhabdomyolysis (tender muscles, dark urine) during acute episodes.

10.2 Laboratory Tests and Functional Studies

Baseline laboratories include serum CK, lactate, myoglobin, renal function (creatinine, urea), and urine myoglobin. In GSD XIII, CK may be normal at rest and elevated only during episodes.[2][4][11] Lactate levels may be normal at rest but fail to rise during exercise. Myoglobinuria indicates rhabdomyolysis.

A forearm ischemic exercise test is a key functional study. In this test, the patient performs handgrip exercise under occluded blood flow, and lactate and ammonia are measured. In GSD XIII, lactate fails to rise, whereas ammonia may increase, reflecting glycolytic block.[3] Comi et al. reported no rise in serum lactate with ischemic forearm exercise in their patient.[3] Tarnopolsky notes that absent lactate rise is characteristic of several glycogen and glycolysis disorders, and test patterns help differentiate them.[2]

Electromyography (EMG) may show mild myopathic changes or be normal; there is no specific EMG signature. Exercise testing (cardiopulmonary) may reveal early fatigue and abnormal lactate kinetics, though these are nonspecific.

10.3 Muscle Biopsy and Histopathology

Muscle biopsy provides critical diagnostic information. In GSD XIII, histology shows normal or minimally myopathic fibers with focal sarcoplasmic glycogen accumulation, and enzyme histochemistry reveals reduced β‑enolase activity.[3][4] Ultrastructural analysis demonstrates glycogen β particle accumulation. Immunohistochemistry and immunoblotting show dramatically reduced β‑enolase protein compared to controls, with normal α‑enolase.[3]

These findings support the diagnosis of muscle enolase deficiency and differentiate GSD XIII from other metabolic myopathies. For example, McArdle disease shows absent myophosphorylase staining, and Pompe disease shows lysosomal glycogen accumulation.[2] In GSD XIII, lysosomes are normal, and glycogen accumulation is non‑lysosomal.

10.4 Genetic Testing and the Role of Biochemical Confirmation

Genetic testing is essential to confirm ENO3 mutations. Options include targeted ENO3 sequencing, glycogen storage disease gene panels, whole‑exome sequencing (WES), or whole‑genome sequencing (WGS).[9][12][14][16] Genomics England’s PanelApp classifies ENO3 as a “green” gene (high evidence) on glycogen storage disease panels, indicating that pathogenic variants in this gene are recognized causes of disease and should be reported.[9]

However, Wigley et al. (2019) highlight that genomic identification of ENO3 variants is not sufficient to confirm disease; biochemical testing of β‑enolase activity in muscle remains necessary to validate pathogenicity.[8] They argue that in the genomic era, where many variants are detected, functional assays are needed to avoid misclassification, especially for variants currently labeled as VUS in ClinVar.[8][16] This is particularly important in ultra‑rare diseases where population and segregation data are sparse.

ClinVar entries such as c.467G>A (p.Gly156Asp) provide variant‑level information, but clinical laboratories must interpret these findings in light of biochemical evidence and clinical phenotype.[16] Single‑gene ENO3 testing may be performed when muscle enolase deficiency is suspected, but panel or exome approaches are often used for undiagnosed metabolic myopathy. WGS has not yet proven uniquely beneficial in GSD XIII beyond exome sequencing, given the monogenic nature and coding‑region localization of known variants.

Chromosomal microarray, karyotyping, and FISH are not useful, as structural chromosomal abnormalities have not been implicated. Mitochondrial DNA testing is not relevant. Repeat expansion testing is not indicated.

10.5 Differential Diagnosis

Differential diagnosis of GSD XIII includes other metabolic myopathies with exercise intolerance and rhabdomyolysis. Key conditions include:

McArdle disease (GSD V, PYGM deficiency), which presents with early fatigue, myalgia, and frequent rhabdomyolysis, with absent lactate rise on exercise test and increased glycogen in muscle.[2] Muscle biopsy shows absent myophosphorylase.

Tarui disease (PFK deficiency), which causes exercise intolerance and hemolytic anemia, with abnormal lactate response and specific biochemical signature.[2]

PGAM2 deficiency, aldolase A deficiency, and other glycolytic enzyme defects, which present with similar exertional symptoms but have distinct enzymatic and genetic profiles.[2]

Mitochondrial myopathies such as MT‑CO3‑related disease, which can present with recurrent rhabdomyolysis and myopathy, but show COX‑negative fibers and isolated complex IV deficiency rather than glycolytic enzyme deficiencies.[13]

Idiopathic recurrent rhabdomyolysis, sickle cell trait, and drug‑induced myopathy must also be considered.

GSD XIII can be differentiated by the combination of muscle β‑enolase deficiency, ENO3 mutations, absent lactate rise with ischemic exercise, and muscle glycogen accumulation. Panel testing that includes ENO3 can identify the gene, and biochemical assays confirm the lesion.[2][3][4][8][9]

10.6 Screening and Asymptomatic Testing

Routine population screening for GSD XIII is not conducted, given its extreme rarity and lack of specific early interventions beyond lifestyle adaptation. Newborn screening panels focus on more prevalent metabolic disorders and do not include ENO3.[5][10] Carrier screening for ENO3 is not standard, although family members of affected individuals may be offered targeted testing for known variants.[12][16]

Asymptomatic individuals with family history may undergo ENO3 genetic testing and muscle enzyme assays. Cascade screening can identify carriers and inform reproductive decision‑making. However, no guidelines exist specifically for GSD XIII; general metabolic and genetic counseling principles apply.

11. Outcome and Prognosis

11.1 Survival, Mortality, and Life Expectancy

No deaths directly attributable to GSD XIII have been reported in the literature. The disease appears compatible with normal life expectancy, provided that rhabdomyolysis episodes are managed appropriately and kidney injury is avoided.[2][3][4][11] Orphanet and Malacards do not list increased mortality, and IAMGSD describes the outlook as good with avoidance of intense exercise.[5][10][11]

However, rhabdomyolysis carries acute risks, including hyperkalemia, arrhythmias, and acute renal failure, which can be life‑threatening if untreated. Therefore, while chronic mortality risk may not be elevated, acute episodes require careful management to prevent complications. There are no large epidemiologic data sets to quantify mortality rates, but case reports suggest favorable outcomes.

11.2 Morbidity, Disability, and Long‑Term Functional Outcomes

Morbidity in GSD XIII consists mainly of chronic exercise intolerance and episodic rhabdomyolysis. Disability outcomes depend on lifestyle adaptation. Individuals who avoid high‑intensity exercise and adhere to recommended physical activity patterns may experience minimal functional impairment, able to perform daily tasks and moderate aerobic activities.[2][3][4][11] Those who insist on intense competitive sports or occupations requiring maximal exertion may suffer recurrent episodes and progressive muscle damage, leading to limitations.

No formal disability scores or International Classification of Functioning (ICF) assessments have been performed in GSD XIII. Extrapolation from similar metabolic myopathies suggests mild limitations in mobility and physical endurance, with possible restrictions in employment that demands heavy physical labor. Cognitive function and social participation are generally preserved.

11.3 Quality of Life Measures

Quality of life in GSD XIII has not been formally quantified using instruments such as SF‑36 or EQ‑5D, but clinical narratives imply that physical functioning and vitality are affected by exercise intolerance and fear of rhabdomyolysis episodes.[2][3][4][11] Patients may experience anxiety about physical exertion, avoid social activities involving sports, and adjust lifestyle to minimize symptoms. Psychological adaptation varies; some individuals accept limitations and maintain overall well‑being, while others may struggle with reduced participation.

In the absence of disease‑specific tools, general quality of life metrics from metabolic myopathy cohorts can be considered representative. Physical function scores are typically reduced, whereas mental health scores remain near normal.[2] The degree to which GSD XIII affects quality of life likely depends on severity of symptoms, frequency of episodes, and effectiveness of preventive strategies.

11.4 Prognostic Factors and Biomarkers

Prognostic factors in GSD XIII include residual β‑enolase activity, lifestyle behaviors, and early diagnosis. Higher residual enzyme activity may correlate with milder symptoms and lower risk of rhabdomyolysis.[3][4][11] Individuals who adopt preventive exercise regimens and avoid triggers have better outcomes.[11] Early diagnosis enables targeted counseling and reduces acute complications.

Biomarkers such as CK and myoglobin are useful for monitoring acute episodes but do not predict long‑term prognosis. Genetic markers (specific ENO3 variants) may eventually be correlated with phenotype severity, but current data are insufficient. No prognostic molecular biomarkers have been validated.

12. Treatment and Management

12.1 Lifestyle and Exercise Prescription

There is no specific pharmacologic treatment for GSD XIII; management is primarily supportive and lifestyle‑based. IAMGSD states that there is no specific treatment and recommends avoiding anaerobic activity, highlighting that the outlook is good with avoidance of intense exercise.[11] Tarnopolsky’s review emphasizes that therapy for glycogen storage diseases with exercise‑induced symptoms, including ENO3 deficiency, involves lifestyle adaptation and carefully titrated exercise programmes.[2]

Patients should be counseled to favor moderate, aerobic exercise over high‑intensity, anaerobic activities. Activities like walking, cycling at moderate pace, and swimming can be encouraged, with gradual progression and attention to symptoms. Warm‑up and cool‑down periods help prepare muscle metabolism and reduce abrupt demands. Interval training with moderate intensity may be tolerated, whereas sprinting and maximal effort should be avoided.

Exercise prescriptions should be individualized, taking into account baseline fitness, comorbidities, and personal preferences. Physical therapists and exercise physiologists familiar with metabolic myopathies can design appropriate programmes. Suggested NCIT terms for interventions include Physical Therapy (NCIT:C4962), Exercise Therapy (NCIT:C15273), and Patient Education (NCIT:C17046).

12.2 Management of Acute Rhabdomyolysis

When rhabdomyolysis occurs, standard acute management protocols apply. This includes prompt recognition, hospital evaluation, aggressive intravenous hydration to prevent renal injury, monitoring of electrolytes (especially potassium), and management of complications.[2][4][11] Myoglobinuria and high CK levels guide treatment intensity. Dialysis may be required in severe cases with renal failure.

Preventive strategies include avoiding recurrence by modifying exercise patterns and addressing underlying metabolic myopathy through diagnosis and counseling. IAMGSD recommends following rhabdomyolysis prevention advice from McArdle disease management, given similarities.[11]

NCIT terms relevant to acute management include Fluid Therapy (NCIT:C28254), Electrolyte Replacement Therapy (NCIT:C28943), and Hospitalization (NCIT:C25193).

12.3 Pharmacotherapy and Nutritional Approaches

No specific drugs target β‑enolase or enhance ENO3 activity. Pharmacotherapy in GSD XIII is limited to symptom management (analgesics for myalgia) and treatment of complications (renal support). Nutritional approaches may include ensuring adequate caloric and carbohydrate intake, but there is no evidence for a disease‑specific diet.

In other glycolytic myopathies, sucrose ingestion before exercise has been explored to provide rapid glucose; in McArdle disease, this can improve exercise tolerance.[2] Whether such strategies benefit GSD XIII is uncertain, given the distal glycolytic block. High‑protein diets or ketogenic diets are not recommended without evidence, as they may impose additional metabolic stress.

Pharmacogenomic considerations are minimal, as no disease‑specific pharmacotherapy exists. However, general awareness of drug–myopathy interactions is important.

12.4 Advanced Therapeutics and Research Directions

Advanced therapeutics such as gene therapy, CRISPR editing, or RNA‑based therapies have not been applied to GSD XIII, and no clinical trials are registered specifically for ENO3 gene therapy. The rarity of the disease limits commercial and research interest. However, in principle, gene replacement therapy delivering a functional ENO3 gene to skeletal muscle or CRISPR‑mediated correction of pathogenic variants could restore β‑enolase activity.

Future research may involve patient‑derived induced pluripotent stem cells (iPSCs) differentiated into muscle cells, enabling in vitro modeling of ENO3 deficiency and screening of small molecules that stabilize mutant enolase. Functional genomics screens (CRISPR, RNAi) could explore compensatory pathways.

At present, these are speculative, and treatment remains supportive.

13. Prevention

13.1 Primary Prevention

Primary prevention of GSD XIII, defined as preventing occurrence of disease, is limited by its genetic nature. Carrier screening and reproductive counseling could theoretically reduce incidence by informing at‑risk couples of reproductive options. However, given the extreme rarity and lack of population screening, primary prevention is largely confined to families with known ENO3 variants.

Genetic counseling can explain autosomal recessive inheritance, carrier risks, and options such as preimplantation genetic diagnosis (PGD) or prenatal testing for ENO3 variants. ACMG and NSGC guidelines for genetic counseling in metabolic disorders apply, though no disease‑specific guidelines exist.

13.2 Secondary Prevention: Early Detection and Screening

Secondary prevention involves early detection and management of disease to prevent complications. In GSD XIII, early diagnosis can prevent severe rhabdomyolysis and guide safe exercise, thereby reducing morbidity. Clinicians should consider ENO3 testing in patients with unexplained exercise intolerance and rhabdomyolysis, especially when other glycogen and glycolysis disorders have been ruled out.

Screening programmes for newborns currently do not include ENO3, and given the adult onset, universal newborn screening is not justified. However, targeted screening of family members (cascade screening) can identify affected individuals and carriers. As genomic sequencing expands, incidental identification of ENO3 variants may prompt evaluation, highlighting the need for awareness of muscle enolase deficiency.

13.3 Tertiary Prevention: Preventing Complications

Tertiary prevention in GSD XIII focuses on preventing complications such as recurrent rhabdomyolysis, acute kidney injury, and chronic disability. This includes educating patients about triggers, advising on safe exercise, monitoring CK and renal function after episodes, and managing comorbidities that increase risk.

Psychosocial support can help patients adapt to lifestyle changes and maintain mental health. Rehabilitation programmes, including physical therapy, can optimize functional capacity without triggering symptoms. These strategies align with general metabolic myopathy management.

14. Other Species and Natural Disease

14.1 ENO3 Orthologs and Comparative Biology

Orthologous ENO3 genes exist in many vertebrate species, including mice, rats, and other mammals, reflecting the evolutionary conservation of glycolytic pathways. NCBI Gene lists ENO3 orthologs across species, with similar expression in skeletal muscle.[14] Enolase isoenzymes have been studied in animal models, showing developmental switches and tissue specificity analogous to humans.

However, naturally occurring ENO3‑related muscle disease has not been described in companion animals or livestock in major veterinary databases such as OMIA. Enolase deficiency in animals, if present, is unreported or extremely rare. Comparative pathology thus focuses more on general metabolic myopathies than on ENO3‑specific conditions.

14.2 Zoonotic Potential and Cross‑Species Susceptibility

GSD XIII is a genetic, non‑infectious disease with no zoonotic potential. Cross‑species susceptibility to ENO3 mutations would depend on analogous genetic variants and inheritance patterns, but there is no evidence of such conditions. Veterinary relevance is limited.

15. Model Organisms and Experimental Systems

15.1 Existing Models

Specific ENO3 knockout or knock‑in animal models of GSD XIII have not been prominently reported in public model organism databases, and no widely used mouse or zebrafish models of muscle β‑enolase deficiency are referenced in the provided sources. Enolase isoenzymes have been studied in rodents, and developmental switches in enolase expression have been documented, but disease models mimicking human GSD XIII are not well characterized.[14]

The absence of documented models limits experimental exploration of pathophysiology and therapy. However, general principles from glycolytic enzyme knockouts and metabolic myopathy models can be extrapolated.

15.2 Potential Modeling Strategies

Potential strategies for modeling GSD XIII include:

Generation of ENO3 knockout mice or muscle‑specific ENO3 conditional knockouts, which could replicate β‑enolase deficiency and allow detailed study of muscle metabolism, exercise responses, and therapeutic interventions. Phenotypes would include exercise intolerance and possibly neonatal lethality if compensation is insufficient.

Creation of knock‑in mice carrying specific human ENO3 missense variants (e.g., Gly156Asp), enabling genotype–phenotype correlation and testing of gene therapy.

Use of patient‑derived iPSCs differentiated into myotubes to create in vitro models of ENO3 deficiency, measuring glycolytic flux, ATP production, and response to interventions.

Development of cell line models expressing mutant ENO3 to study protein stability, interactions, and structural properties.

These models could support research on compensatory metabolic pathways, drug screening, and gene therapy.

15.3 Applications and Limitations

Model organisms would allow detailed mechanistic studies beyond what is possible in humans, including invasive muscle sampling, exercise protocols, and molecular analyses. They could test hypotheses about isoenzyme compensation, mitochondrial adaptation, and long‑term consequences of repeated rhabdomyolysis.

Limitations include potential differences between rodent and human muscle physiology, the rarity of the human disease limiting translational relevance, and the resources required to develop models for ultra‑rare conditions. Ethical considerations and prioritization of research focus also influence model development.

Conclusion and Future Directions

Glycogen storage disease type XIII (muscle β‑enolase deficiency, ENO3) is a paradigmatic ultra‑rare inborn error of metabolism that illuminates the interplay between genetic determinants of muscle energy metabolism and environmental triggers such as exercise. Its pathophysiology is rooted in autosomal recessive ENO3 mutations that severely reduce β‑enolase activity in skeletal muscle, creating a distal glycolytic block at the 2‑phosphoglycerate to phosphoenolpyruvate step and thereby impairing ATP generation during high‑intensity exercise.[2][3][4][5][8][10][11][16][17] Clinically, this manifests as exercise intolerance, myalgia, functional muscle weakness, and episodic rhabdomyolysis with myoglobinuria, often with normal baseline CK and absent lactate rise during ischemic forearm exercise.[2][3][4][5][11]

From a nosologic standpoint, GSD XIII is best classified as a glycolysis disorder and glycogen storage disease affecting skeletal muscle, situated among metabolic myopathies with exertional symptoms. Its identifiers span OMIM:612932, Orphanet:99849, MONDO:0013046, MedGen:C2752027, and GARD:2125, and it carries ICD‑10 E74.0 and ICD‑11 5C51.3 codes.[1][5][6][10][12][16] Synonyms such as “muscle enolase deficiency,” “glycogenosis type 13,” and “GSDXIII” reflect its biochemical and clinical facets.[4][5][10][11]

Despite its rarity, GSD XIII holds conceptual significance. It demonstrates how tissue‑specific expression of an isoenzyme (β‑enolase) can shape disease phenotype, how residual activity modulates severity, and how gene–environment interactions define clinical expression. The disease exemplifies the limits of genomic medicine in ultra‑rare conditions: variants such as c.467G>A (p.Gly156Asp) are supported by functional data but remain VUS in ClinVar due to sparse case evidence, necessitating ongoing reliance on biochemical confirmation via muscle enzyme assays.[3][8][16] Wigley et al. (2019) underscore this point in their call for biochemical testing in the genomic era.[8]

Diagnostic approaches integrate clinical suspicion, functional testing (ischemic forearm test), muscle biopsy (glycogen accumulation and absent β‑enolase), and genetic testing (ENO3 sequencing).[2][3][4][8][9] Differential diagnoses include McArdle disease, Tarui disease, PGAM2 deficiency, aldolase A deficiency, and mitochondrial myopathies such as MT‑CO3‑related disease.[2][13] Treatment is supportive, centered on lifestyle adaptation and avoidance of intense anaerobic exercise, with management of acute rhabdomyolysis episodes and general rehabilitation.[2][11] No disease‑specific pharmacotherapy or gene therapy exists, and advanced therapeutics remain speculative.

Many aspects of GSD XIII remain incompletely characterized. Epidemiologic data are limited to estimates of ultra‑rarity (<1/1,000,000 prevalence) and a handful of cases; natural history and long‑term outcomes are inferred rather than systematically documented.[4][5][10][11] Genotype–phenotype correlations, including the impact of specific ENO3 variants and residual activity levels, need further study. Epigenetic regulation, modifier genes, and compensatory metabolic pathways are unexplored. Model organisms and in vitro systems could advance mechanistic understanding and open avenues for potential therapies.

Future directions include:

Systematic collection of case data through international registries and rare disease networks, enabling more robust characterization of phenotype, genotype, and natural history.

Integration of ENO3 into standardized metabolic myopathy gene panels and improved variant interpretation frameworks, including functional assays, to move key variants from VUS to pathogenic classification.

Development of experimental models, such as ENO3 knock‑in/knockout mice and patient‑derived myotube cultures, to study glycolytic dynamics, isoenzyme compensation, and therapeutic interventions.

Exploration of tailored exercise prescriptions and nutritional strategies to optimize quality of life while minimizing risk, potentially informed by detailed exercise physiology studies like those of Toscano et al.[17]

Consideration of gene‑based therapies in the longer term, leveraging advances in muscle‑targeted gene delivery and genome editing.

In the meantime, GSD XIII serves as a compelling example for clinicians and researchers of how precise biochemical defects manifest in muscle function, how rare diseases challenge diagnostic paradigms, and how thoughtful integration of clinical, biochemical, and genetic data is essential in the era of high‑throughput genomics.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.